Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?
Lancet Oncol
.
2025 Jan;26(1):3-5.
doi: 10.1016/S1470-2045(24)00680-6.
Authors
Cécile Le Pechoux
1
,
Angela Botticella
2
,
Antonin Levy
3
Affiliations
1
Department of Radiation Oncology, Gustave Roussy, Villejuif 94850, France. Electronic address:
[email protected]
.
2
Department of Radiation Oncology, Gustave Roussy, Villejuif 94850, France.
3
Department of Radiation Oncology, Gustave Roussy, Villejuif 94850, France; Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
PMID:
39756443
DOI:
10.1016/S1470-2045(24)00680-6
No abstract available